Close Menu
TechCentralTechCentral

    Subscribe to the newsletter

    Get the best South African technology news and analysis delivered to your e-mail inbox every morning.

    Facebook X (Twitter) YouTube LinkedIn
    WhatsApp Facebook X (Twitter) LinkedIn YouTube
    TechCentralTechCentral
    • News

      World Bank set to back South Africa’s big energy grid roll-out

      20 June 2025

      The algorithm will sing now: why musicians should be worried about AI

      20 June 2025

      Sita hits back at critics, promises faster, automated procurement

      20 June 2025

      The transatlantic race to create the first television

      20 June 2025

      Listed: All the MVNOs in South Africa – 2025 edition

      19 June 2025
    • World

      Watch | Starship rocket explodes in setback to Musk’s Mars mission

      19 June 2025

      Trump Mobile dials into politics, profit and patriarchy

      17 June 2025

      Samsung plots health data hub to link users and doctors in real time

      17 June 2025

      Beijing’s chip champions blacklisted by Taiwan

      16 June 2025

      China is behind in AI chips – but for how much longer?

      13 June 2025
    • In-depth

      Meta bets $72-billion on AI – and investors love it

      17 June 2025

      MultiChoice may unbundle SuperSport from DStv

      12 June 2025

      Grok promised bias-free chat. Then came the edits

      2 June 2025

      Digital fortress: We go inside JB5, Teraco’s giant new AI-ready data centre

      30 May 2025

      Sam Altman and Jony Ive’s big bet to out-Apple Apple

      22 May 2025
    • TCS

      TCS+ | AfriGIS’s Helen Hulett on how tech can help resolve South Africa’s water crisis

      18 June 2025

      TechCentral Nexus S0E2: South Africa’s digital battlefield

      16 June 2025

      TechCentral Nexus S0E1: Starlink, BEE and a new leader at Vodacom

      8 June 2025

      TCS+ | The future of mobile money, with MTN’s Kagiso Mothibi

      6 June 2025

      TCS+ | AI is more than hype: Workday execs unpack real human impact

      4 June 2025
    • Opinion

      South Africa pioneered drone laws a decade ago – now it must catch up

      17 June 2025

      AI and the future of ICT distribution

      16 June 2025

      Singapore soared – why can’t we? Lessons South Africa refuses to learn

      13 June 2025

      Beyond the box: why IT distribution depends on real partnerships

      2 June 2025

      South Africa’s next crisis? Being offline in an AI-driven world

      2 June 2025
    • Company Hubs
      • Africa Data Centres
      • AfriGIS
      • Altron Digital Business
      • Altron Document Solutions
      • Altron Group
      • Arctic Wolf
      • AvertITD
      • Braintree
      • CallMiner
      • CYBER1 Solutions
      • Digicloud Africa
      • Digimune
      • Domains.co.za
      • ESET
      • Euphoria Telecom
      • Incredible Business
      • iONLINE
      • Iris Network Systems
      • LSD Open
      • NEC XON
      • Network Platforms
      • Next DLP
      • Ovations
      • Paracon
      • Paratus
      • Q-KON
      • SevenC
      • SkyWire
      • Solid8 Technologies
      • Telit Cinterion
      • Tenable
      • Vertiv
      • Videri Digital
      • Wipro
      • Workday
    • Sections
      • AI and machine learning
      • Banking
      • Broadcasting and Media
      • Cloud services
      • Contact centres and CX
      • Cryptocurrencies
      • Education and skills
      • Electronics and hardware
      • Energy and sustainability
      • Enterprise software
      • Fintech
      • Information security
      • Internet and connectivity
      • Internet of Things
      • Investment
      • IT services
      • Lifestyle
      • Motoring
      • Public sector
      • Retail and e-commerce
      • Science
      • SMEs and start-ups
      • Social media
      • Talent and leadership
      • Telecoms
    • Events
    • Advertise
    TechCentralTechCentral
    Home » David Glance » Garage biotech promises to disrupt big pharma

    Garage biotech promises to disrupt big pharma

    By David Glance6 May 2016
    Twitter LinkedIn Facebook WhatsApp Email Telegram Copy Link
    News Alerts
    WhatsApp

    david-glance-180Pharmaceutical companies typically develop new drugs with thousands of staff and budgets that run into the billions of dollars. One estimate puts the cost of bringing a new drug to market at US$2,6bn with others suggesting that it could be double that cost at $5bn.

    One man, Atul Butte, director of the University of California Institute of Computational Health Sciences, believes that like other Silicon Valley start-ups, almost anyone can bring a drug to market from their garage with just a computer, the Internet and freely available data.

    In a talk given at the Science on the Swan conference held in Perth in Australia this week, Butte outlined the process for an audience of local and international scientists and medics.

    The starting point is the genetic data from thousands of studies on humans, mice and other animals that is now freely available on sites from the National Institute of Health and the European Molecular Biology Laboratory. The proliferation of genetic data from experiments has been driven by the ever decreasing cost of sequencing genetic information using gene chip technologies.

    Butte, students and research staff have found a range of different ways of using this data to look for new drugs. In one approach, they have constructed a map of how the genetic profiles of people with particular diseases are related to each other. In particular, to look for diseases with very similar genetic profiles.

    Having done that, they noticed that the genetic profile of people with heart conditions were very closely related to that of the much rarer condition of muscular dystrophy. What this potentially suggested was that drugs that work for one condition could potentially work in the other. This process of discovering other uses of drugs, called “drug repositioning”, is not new. Drugs like Viagra were originally used for treatment of cardiovascular conditions. The difference is that Viagra’s repositioned use resulted from the observation of side-effects in patients taking the drug for its original intended purpose.

    Butte on the other hand is using “big data” and computers to show that given the close relationship in the genetic profile of two diseases, the potential crossover effect of drugs working for one condition working in another.

    startup-640

    Still in the garage, the next step from discovering a potential drug is to test if it actually works in an experimental setting on animals. Here again, Butte has turned to the Internet and sites like Assay Depot. This is a site, structured like Amazon, from which a researcher can order an experiment to be carried out to test a drug on a range of animal models. It is literally a case of choosing the experiment type you want, adding it to a shopping cart, paying by credit card and getting the experimental results mailed back in a few weeks’ time. “Shoppers” are given the choice of laboratory they want to use, including a choice of which country the lab is based.

    Once a new use for a drug has been shown to work in an animal model, the next step would be to test the drug in humans, get approval for the use of the drug for that condition and then finally take the drug to market.

    In California, where Butte works, this has involved spinning out companies with money from investors, a process that he and his students have done after the discovery of new uses for several drugs.

    As with cloud computing and cloud labour, “cloud research” works because services can be sourced inexpensively from laboratories that have expertise in particular areas. In one case, Butte related a story of needing to see if a drug would cure inflammatory bowel diseases in rats which involved performing colonoscopies on the animals. This expertise and equipment was available somewhere in the world, made accessible through a simple online shopping interface.

    The entire process outlined for this type of drug discovery, testing and commercialisation, radically changes the nature of how quickly and cheaply, new drugs can be brought to market to treat conditions for which there would still be few options.

    None of this would be possible without the sharing of data and it highlights how the growth of availability of open research data will be able to fuel a range of uses that would not have been foreseen when the individual experiments were being carried out.The Conversation

    • David Glance is director of the UWA Centre for Software Practice, University of Western Australia
    • This article was originally published on The Conversation


    Atul Butte David Glance
    Subscribe to TechCentral Subscribe to TechCentral
    Share. Facebook Twitter LinkedIn WhatsApp Telegram Email Copy Link
    Previous ArticleTshwane defies treasury on broadband project
    Next Article Muthambi in scathing attack on SA media

    Related Posts

    What should gov’t be doing about the rise of AI?

    6 November 2017

    So, what exactly is an initial coin offering?

    28 September 2017

    Cars becoming like phones, needing regular software updates

    11 September 2017
    Company News

    Making IT happen: how Trade Link gears up to enable SA retail strategies

    20 June 2025

    Why parents choose CambriLearn for online education

    19 June 2025

    Disrupt first, ask questions later – the uncomfortable truth about incident response

    18 June 2025
    Opinion

    South Africa pioneered drone laws a decade ago – now it must catch up

    17 June 2025

    AI and the future of ICT distribution

    16 June 2025

    Singapore soared – why can’t we? Lessons South Africa refuses to learn

    13 June 2025

    Subscribe to Updates

    Get the best South African technology news and analysis delivered to your e-mail inbox every morning.

    © 2009 - 2025 NewsCentral Media

    Type above and press Enter to search. Press Esc to cancel.